Clinical Trial Update: Β-Thalassemia Treatment with KL003 Cell Injection [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating KL003 cell injection for transfusion-dependent beta-thalassemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia
• Transfusion-dependent Beta-thalassemia

Drugs mentioned

• KL003 cell injection

Snippet

Sponsor: Kanglin Biotechnology (Hangzhou) Co., Ltd. | Conditions: Transfusion-dependent Beta-Thalassemia | Phase 1, Phase 2 | Status: RECRUITING